## Syed Tabish Razi Zaidi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3368120/publications.pdf

Version: 2024-02-01

90 papers 2,268 citations

279798 23 h-index 254184 43 g-index

91 all docs 91 docs citations

times ranked

91

2994 citing authors

#	Article	IF	CITATIONS
1	Why hospital-based healthcare professionals do not report adverse drug reactions: a mixed methods study using the Theoretical Domains Framework. European Journal of Clinical Pharmacology, 2022, 78, 1165-1175.	1.9	10
2	Social distancing and the use of PPE by community pharmacy personnel: Does evidence support these measures?. Research in Social and Administrative Pharmacy, 2021, 17, 456-459.	3.0	34
3	Personal protective practices and pharmacy services delivery by community pharmacists during COVID-19 pandemic: Results from a national survey. Research in Social and Administrative Pharmacy, 2021, 17, 1832-1837.	3.0	45
4	Consistency of recommendations from clinical practice guidelines for the management of critically ill COVID-19 patients. European Journal of Hospital Pharmacy, 2021, 28, 42-46.	1.1	8
5	An international inventory of antimicrobial stewardship (AMS) training programmes for AMS teams. Journal of Antimicrobial Chemotherapy, 2021, 76, 1633-1640.	3.0	8
6	Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting. Journal of Thrombosis and Thrombolysis, 2021, 52, 646-653.	2.1	32
7	Attitudes to Drug Use in Residential Aged Care Facilities: A Cross-Sectional Survey of Nurses and Care Staff. Drugs and Aging, 2021, 38, 697-711.	2.7	10
8	Prevalence, characteristics, and reporting of adverse drug reactions in an Australian hospital: a retrospective review of hospital admissions due to adverse drug reactions. Expert Opinion on Drug Safety, 2021, 20, 1267-1274.	2.4	16
9	Validation and implementation of a national survey to assess antimicrobial stewardship awareness, practices and perceptions amongst community pharmacists in Australia. Journal of Global Antimicrobial Resistance, 2020, 21, 28-33.	2.2	4
10	Health information overload among health consumers: A scoping review. Patient Education and Counseling, 2020, 103, 15-32.	2.2	95
11	Effectiveness of interventions to improve adverse drug reaction reporting by healthcare professionals over the last decade: A systematic review. Pharmacoepidemiology and Drug Safety, 2020, 29, 1-8.	1.9	33
12	Mortality in COVID-19 patients with acute respiratory distress syndrome and corticosteroids use: a systematic review and meta-analysis. Expert Review of Respiratory Medicine, 2020, 14, 1149-1163.	2.5	184
13	Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2020, 50, 814-821.	2.1	92
14	Mortality and Disease Severity Among COVID-19 Patients Receiving Renin-Angiotensin System Inhibitors: A Systematic Review and Meta-analysis. American Journal of Cardiovascular Drugs, 2020, 20, 571-590.	2.2	34
15	Management of Outpatient Warfarin Therapy amid COVID-19 Pandemic: A Practical Guide. American Journal of Cardiovascular Drugs, 2020, 20, 301-309.	2.2	24
16	Pyridine levels in ceftazidime – peritoneal dialysis admixtures stored at body temperature. Peritoneal Dialysis International, 2020, 40, 171-178.	2.3	4
17	Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions. Peritoneal Dialysis International, 2020, 40, 470-476.	2.3	8
18	Medication Adherence, Burden and Health-Related Quality of Life in Adults with Predialysis Chronic Kidney Disease: A Prospective Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 371.	2.6	31

#	Article	IF	CITATIONS
19	Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19. American Journal of Cardiovascular Drugs, 2020, 20, 217-221.	2.2	23
20	Effect of the black triangle scheme and its online educational campaign on the quantity and quality of adverse drug event reporting in Australia: a time series analysis. Expert Opinion on Drug Safety, 2020, 19, 747-753.	2.4	11
21	Medication Regimen Complexity and Hospital Readmission in Older Adults With Chronic Kidney Disease. Annals of Pharmacotherapy, 2019, 53, 28-34.	1.9	18
22	Medication adherence assessment practices in dialysis settings: A survey of renal nurses' perceptions. Journal of Clinical Nursing, 2019, 28, 528-537.	3.0	4
23	Levofloxacin: Insights Into Antibiotic Resistance and Product Quality. Frontiers in Pharmacology, 2019, 10, 881.	3.5	18
24	Effect of pharmacistâ€led medication review on medication appropriateness in older adults with chronic kidney disease. Journal of Pharmacy Practice and Research, 2019, 49, 471-476.	0.8	6
25	Medication-Related Factors and Hospital Readmission in Older Adults with Chronic Kidney Disease. Journal of Clinical Medicine, 2019, 8, 395.	2.4	8
26	Health Literacy Studies Conducted in Australia: A Scoping Review. International Journal of Environmental Research and Public Health, 2019, 16, 1112.	2.6	31
27	Adherence assessment practices in haemodialysis settings: A qualitative exploration of nurses and pharmacists' perspectives. Journal of Clinical Nursing, 2019, 28, 2197-2205.	3.0	3
28	Anaesthetists' drug dosing practices in class III obese surgical patients: A bi-national survey. Anaesthesia and Intensive Care, 2019, 47, 516-521.	0.7	1
29	The effect of hospitalization on potentially inappropriate medication use in older adults with chronic kidney disease. Current Medical Research and Opinion, 2019, 35, 1119-1126.	1.9	11
30	Prophylactic Cefazolin Dosing and Surgical Site Infections: Does the Dose Matter in Obese Patients?. Obesity Surgery, 2019, 29, 159-165.	2.1	21
31	Evaluation of a chronic kidney disease risk assessment service in community pharmacies. Nephrology, 2019, 24, 301-307.	1.6	3
32	Chronic kidney disease monitoring in Australian general practice. Australian Journal of General Practice, 2019, 48, 132-137.	0.8	8
33	Stability of dobutamine in continuous ambulatory delivery devices. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 530-535.	1.5	3
34	Stability of Cefazolin in Polyisoprene Elastomeric Infusion Devices. Clinical Therapeutics, 2018, 40, 664-667.	2.5	8
35	Patient satisfaction with a chronic kidney disease risk assessment service in community pharmacies. International Journal of Clinical Pharmacy, 2018, 40, 458-463.	2.1	2
36	Pharmacist participation in antimicrobial stewardship in Australian and French hospitals: a cross-sectional nationwide survey. Journal of Antimicrobial Chemotherapy, 2018, 73, 804-813.	3.0	32

#	Article	lF	CITATIONS
37	Public knowledge of chronic kidney disease evaluated using a validated questionnaire: a cross-sectional study. BMC Public Health, 2018, 18, 371.	2.9	28
38	Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review. Journal of Nephrology, 2018, 31, 27-36.	2.0	9
39	A proposed stepwise approach to reducing medication errors in older people. Research in Social and Administrative Pharmacy, 2018, 14, 207-209.	3.0	3
40	Investigations into the physical and chemical stability of concentrated co-trimoxazole intravenous infusions. European Journal of Hospital Pharmacy, 2018, 25, e102-e108.	1.1	1
41	Physicochemical stability of voriconazole in elastomeric devices. European Journal of Hospital Pharmacy, 2018, 25, e88-e92.	1.1	4
42	Physical and chemical stability of ceftaroline in an elastomeric infusion device. European Journal of Hospital Pharmacy, 2018, 25, e115-e119.	1.1	13
43	Stability of Ceftazidime and Heparin in Four Different Types of Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2018, 38, 49-56.	2.3	9
44	Renal pharmacists' perceptions and current practices of assessing medication adherence in dialysis patients. International Journal of Clinical Pharmacy, 2018, 40, 26-35.	2.1	5
45	Stability of milrinone in continuous ambulatory delivery devices. American Journal of Health-System Pharmacy, 2018, 75, e241-e245.	1.0	0
46	Peri-operative Medication Dosing in Adult Obese Elective Surgical Patients: A Systematic Review of Clinical Studies. Clinical Drug Investigation, 2018, 38, 673-693.	2.2	12
47	Completeness and Legibility of Handwritten Prescriptions in Sana'a, Yemen. Medical Principles and Practice, 2018, 27, 290-292.	2.4	216
48	Australian Community Pharmacists' Experience of Implementing a Chronic Kidney Disease Risk Assessment Service. Preventing Chronic Disease, 2018, 15, E81.	3.4	4
49	Therapeutic Potential of Enoxaparin in Lichen Planus: Exploring Reasons for Inconsistent Reports. Frontiers in Pharmacology, 2018, 9, 586.	3.5	3
50	Perceptions and current practices of community pharmacists regarding antimicrobial stewardship in Tasmania. International Journal of Clinical Pharmacy, 2018, 40, 1380-1387.	2.1	28
51	Stability of Meropenem and Piperacillin/Tazobactam with Heparin in Various Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2018, 38, 430-440.	2.3	11
52	Cost-effectiveness analysis of low versus high dose colistin in the treatment of multi-drug resistant pneumonia in Saudi Arabia. International Journal of Clinical Pharmacy, 2018, 40, 1051-1058.	2.1	13
53	Community pharmacists' knowledge and perspectives of reporting adverse drug reactions in Australia: a cross-sectional survey. International Journal of Clinical Pharmacy, 2018, 40, 878-889.	2.1	46
54	Barriers and strategies to improve influenza vaccination in Pakistan. Journal of Infection and Public Health, 2017, 10, 881-883.	4.1	18

#	Article	IF	CITATIONS
55	Retrospective audit of antimicrobial prescribing practices for acute exacerbations of chronic obstructive pulmonary diseases in a large regional hospital. Journal of Clinical Pharmacy and Therapeutics, 2017, 42, 301-305.	1.5	6
56	Inappropriate prescribing in chronic kidney disease: A systematic review of prevalence, associated clinical outcomes and impact of interventions. International Journal of Clinical Practice, 2017, 71, e12960.	1.7	64
57	Patients' understanding and use of analgesia for postnatal pain following hospital discharge. International Journal of Clinical Pharmacy, 2017, 39, 133-138.	2.1	O
58	Intravenous iron sucrose and ferric carboxymaltose in pregnant patients: an observational study of maternal efficacy and tolerance. Journal of Pharmacy Practice and Research, 2017, 47, 419-425.	0.8	4
59	Medication adherence perspectives in haemodialysis patients: a qualitative study. BMC Nephrology, 2017, 18, 167.	1.8	44
60	Combating Sale of Counterfeit and Falsified Medicines Online: A Losing Battle. Frontiers in Pharmacology, 2017, 8, 268.	3.5	246
61	The Crux of the Medicine Prices' Controversy in Pakistan. Frontiers in Pharmacology, 2017, 8, 504.	3.5	11
62	Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries. Frontiers in Pharmacology, 2017, 8, 546.	3.5	64
63	Antimicrobial knowledge and confidence amongst final year medical students in Australia. PLoS ONE, 2017, 12, e0182460.	2.5	29
64	Perceptions and Practices of Community Pharmacists towards Antimicrobial Stewardship in the State of Selangor, Malaysia. PLoS ONE, 2016, 11, e0149623.	2.5	42
65	Clinical Pathway and Monthly Feedback Improve Adherence to Antibiotic Guideline Recommendations for Community-Acquired Pneumonia. PLoS ONE, 2016, 11, e0159467.	2.5	17
66	Medication Regimen Complexity and Adherence in Haemodialysis Patients: An Exploratory Study. American Journal of Nephrology, 2016, 43, 318-324.	3.1	24
67	Antimicrobial drug use in primary healthcare clinics: a retrospective evaluation. International Journal of Infectious Diseases, 2016, 52, 16-22.	3.3	19
68	Fluoroquinolones., 2016,, 45-52.		0
69	Deâ€mystifying pharmacoeconomics and a suggestive approach to evaluating the costâ€effectiveness of antimicrobial stewardship. Journal of Pharmacy Practice and Research, 2016, 46, 94-99.	0.8	0
70	Stability of Cefepime in pH-Neutral Peritoneal Dialysis Solutions Packaged in Dual-Compartment Bags. Peritoneal Dialysis International, 2016, 36, 457-459.	2.3	5
71	Cephalosporins. , 2016, , 27-38.		0
72	A web-based training program to support chronic kidney disease screening by community pharmacists. International Journal of Clinical Pharmacy, 2016, 38, 1080-1086.	2.1	10

#	Article	IF	Citations
73	Attitude, barriers and facilitators to practice-based research: cross-sectional survey of hospital pharmacists in Saudi Arabia. Journal of Pharmaceutical Policy and Practice, 2016, 9, 4.	2.4	32
74	Stability of Tigecycline in Different Types of Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2016, 36, 410-414.	2.3	13
75	Stability of daptomycin in peritoneal dialysis solutions packaged in dual-compartment infusion bags. European Journal of Hospital Pharmacy, 2016, 23, 57-60.	1.1	2
76	Miscellaneous Agents., 2016,, 117-125.		0
77	Glycopeptides and Antibiotics for Gram-positive Bacterial Infections. , 2016, , 63-76.		0
78	Revisiting the clinical evidence and economics of dexmedetomidine use. Journal of Medical Marketing, 2015, 15, 90-92.	0.2	1
79	Non-Anticoagulant Fractions of Enoxaparin Suppress Inflammatory Cytokine Release from Peripheral Blood Mononuclear Cells of Allergic Asthmatic Individuals. PLoS ONE, 2015, 10, e0128803.	2.5	22
80	Nonadherence to Medication Therapy in Haemodialysis Patients: A Systematic Review. PLoS ONE, 2015, 10, e0144119.	2.5	156
81	Opposing Effects of Low Molecular Weight Heparins on the Release of Inflammatory Cytokines from Peripheral Blood Mononuclear Cells of Asthmatics. PLoS ONE, 2015, 10, e0118798.	2.5	22
82	Metformin utilisation in Australian community and aged care settings. Diabetes Research and Clinical Practice, 2015, 108, 336-341.	2.8	3
83	Applying Pharmacoeconomics in Community and Hospital Pharmacy Research., 2015, , 157-173.		3
84	Factors influencing ceftriaxone use in communityâ€acquired pneumonia: Emergency doctors' perspectives. EMA - Emergency Medicine Australasia, 2014, 26, 591-595.	1.1	10
85	Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. Journal of Clinical Pharmacy and Therapeutics, 2014, 39, 272-276.	1.5	15
86	Using formative evaluation to improve uptake of a web-based tool to support antimicrobial stewardship. Journal of Clinical Pharmacy and Therapeutics, 2013, 38, 490-497.	1.5	13
87	Barriers and Facilitators to Adoption of a Web-based Antibiotic Decision Support System. Southern Med Review, 2012, 5, 42-50.	0.8	11
88	The role of perceptions of clinicians in their adoption of a web-based antibiotic approval system: Do perceptions translate into actions?. International Journal of Medical Informatics, 2008, 77, 33-40.	3.3	38
89	Impact of pharmacist recommendations on the cost of drug therapy in icu patients at a Malaysian hospital. International Journal of Clinical Pharmacy, 2003, 25, 299-302.	1.4	34
90	Contacting patients of a Pakistani hospital about a drug recall. American Journal of Health-System Pharmacy, 2002, 59, 1569-1569.	1.0	2